


Syngene

Putting Science to Work



Science
For People
**ADVANCING
INNOVATION**

Antibody Drug Conjugates

One Partner from
Discovery to
GMP Supply



One Team. One Site.

One Integrated Path for Conjugates

Most ADC programs, whether antibody-drug, peptide-drug, or antibody-oligonucleotide conjugates, are built by stitching together specialist vendors: a biologics or peptide manufacturer, a payload and linker chemistry house, and a separate bioconjugation partner. Every hand-off between them costs time. A technology transfer package gets rebuilt. A new team learns your molecule from scratch. A batch sits in a queue while paperwork catches up.

We closed that gap by building our GMP bioconjugation suite directly inside our commercial biologics facility in Bengaluru (Unit 3). Antibody production and OEB-5 bioconjugation now sit on the same site, alongside our existing commercial-scale payload and linker manufacturing and collocated analytical labs, so your molecule does not have to travel between companies, or even between cities. The result is a more connected path from starting material to conjugated drug substance with fewer interfaces, streamlined technology transfer, and one team supporting your molecule throughout development and manufacturing.

What This Means for Your Program

- **Integrated execution:** Antibody, toxin, peptide, or oligonucleotide synthesis through linker-payload chemistry, bioconjugation, and GMP release
- **Connected analytics:** Analytical and bioanalytical capabilities aligned with development and manufacturing
- **Simplified technology transfer:** One coordinated pathway into GMP manufacturing rather than multiple transfer across vendors

Your Program, from Milligrams to Kilograms



Fewer Handoffs → Integrated Capabilities → Faster Path to GMP

One Integrated Platform, Five Interlocking Parts

Five capability areas, one team, one project plan, spanning target discovery through GMP supply.



Target & Antibody Discovery

Hybridoma, single B-cell and display platforms, feeding straight into conjugate design. Full mAb capability from cell line development through GMP, engineering batches to 4 KL.



Payload & Linker Chemistry

Cytotoxic and non-conventional payloads. Cleavable and non-cleavable linker design, with building blocks kept in stock for 2 to 4 week turnaround.



Bioconjugation

Conjugation chemistries: amine, thiol, site-specific, enzymatic, click, and dual payload, matched to your molecule.



Analytical & Bioassay

In Vitro and *In Vivo* efficacy, DMPK across six species, and a full release and characterization panel, in-house.



GMP Manufacturing & Supply

OEB-5 bioconjugation and HPAPI GMP manufacturing, across Bengaluru, Mangaluru, and Bayview, MD network.

Screen Wide, Commit Narrow

A linker-payload combination that looks good on paper and fails to perform months later is one of the costliest mistakes an ADC program can make. Early linker-payload decisions can define the downstream success of an ADC program. Syngene enables parallel screening of multiple antibody, toxin, peptide, or oligonucleotide combination at 5 mg to 500 mg scale, typically progressing an initial screening plan within two to three weeks, so you choose a lead candidate on cell-based, DAR, and *in vivo* data rather than on assumption.

Antibody discovery, including hybridoma, single B-cell and display platforms, connects directly with same linker-payload design and bioconjugation team, creating an integrated path from target specific binder to optimized conjugation. There is no separate vendor to loop in before conjugate work can start.

Breadth to Explore. Expertise to Select.



Conjugation Chemistries

Lysine, Cysteine, Engineered cysteine (THIOMAB™-type), Re-bridging method, enzymatic (site-specific), matched to your molecule.



Deep Chemistry Track Record

200+ auristatin analogs, 80+ camptothecin analogs, 200+ duocarmycins, plus maytansinoids, PBDs and tubulysins.



Integrated Antibody Discovery

Hybridoma, single B-cell and display platforms, through to lead antibody selection.



In Vivo & DMPK Support

PK, xenograft efficacy and safety across 6 species. 100+ DMPK studies run across 20+ ADCs.

Linker Selection by Design

Physicochemical Properties

- Hydrophilicity, polar groups
- Linker length and rigidity

Serum Stability

- Strategies to reduce hydrophobicity and aggregation
- Increased steric hindrance
- Unnatural amino acid incorporation

Release Mechanism

- Tumor-specific enzyme cleavable
- TME cleavable
- Non-cleavable

Linker building blocks are kept in stock, so most linker-payload synthesis complete in 2 to 4 weeks.

Payload Class	Analog Synthesized
Auristatins (MMAE, MMAF)	200+
Camptothecin analogs (SN-38, Exatecan)	80+
Duocarmycins	200+
Maytansinoids (DM1, DM4)	50+
Pyrrolobenzodiazepines (PBDs)	~10
Tubulysins	3, including a 27-step total synthesis

A candidate that progresses through our discovery screen has already been evaluated against critical development risks including aggregation, serum stability, and DAR consistency. Development therefore begins with a better characterized candidate and fewer unresolved questions. Share your target, payload class, and modality-antibody, peptide, or oligonucleotide and we can design a screening strategy around your molecule.

The Process that Leaves The Bench is Designed to Enter GMP

Our development strategy focuses on scaling and optimizing the process, not rebuilding it. Conjugation and linker-payload chemistry progress from milligram to tens-of-gram scale in 2 to 4 week cycles, with equipment strategy, analytical methods, and GMP requirements considered from the outset. This creates a more direct path to GMP, reducing technology-transfer complexity and preserving process knowledge as your program advances.



Scale-Up Cycles

Progression to tens of grams in 3 to 4 week cycles, with DAR assay development built for GMP suitability from the outset.



Optimization Throughput

Evaluation of 3 to 4 conjugates per scientist per week at 2 to 5 mg scale during process optimization.



HPAPI Development Facility

Jacketed reactors to 5 L, ISO 8 isolators, OEB 4/5 handling, -30 °C to 150 °C range.



Clinical PK & ADA

Method development, validation and analysis run alongside your material, not queued behind it.

Scale-Up, in One Continuous Line, Chemistry and Biologics Together



Payload & Linker PD

- 25 ml to 5 L reactors
- mg to 200 g batches



cGMP Bioconjugation

- 60 L to 630 L reactors
- Up to 20 kg per batch



mAb GMP Manufacturing

- CLD through GMP DS & DP
- Engineering batches to 4 KL

The reactor fit, the analytical methods and the batch plan are validated at the same sites that will run your GMP batch. There is no new team to convince and no new equipment to qualify.

Bring your development stage process or let our team build one from your discovery data, and we will lay out a scale-up plan with timelines.

Manufacturing Capacity That Grows with Your Program

Two sites in India, one in the U.S.: Bengaluru and Mangaluru, and Bayview, Maryland. One quality system runs across all three, which means an ADC program can move from non-clinical tox material through clinical and larger-volume supply without requalifying a new facility, training a new team, or re-proving a process along the way.



Bengaluru (Unit 3)

- OEB-5 bioconjugation suite
- 50 g to 1000 g process capacity
- Co-located mAb production & QC



Mangaluru

- HPAPI GMP manufacturing
- 60 L to 630 L reactors
- Up to 20 kg per batch



Bayview, Maryland, U.S.

- 16 KL SUB capacity
- 50 L to 4 KL SUBs
- Dedicated mammalian cell culture

Containment and Release

• High-Containment Processing

Single-use OEB-5 containment with 100 % once-through plus dual-exhaust HEPA with BIBO, Grade D closed processing

• Science-Based Technology Transfer

First-principles scale-up incorporating equipment fit and batch plan assessment as part of the transfer strategy

• Integrated Testing and Release

Typically, about 1 week of processing, 4 weeks of testing and release

Category	Representative Tests
Purity & aggregate	SEC-HPLC, CE-SDS, and orthogonal purity methods
DAR	Absorbance, Mass based (intact and reduced), chromatographic DAR assessment (HIC)
Charge profile	IEX-HPLC, icIEF
Impurities	Free drug / protein, residual solvent, water, endotoxin, bioburden
Extended characterization	CD, fluorescence, LC-HRMS peptide mapping & sequencing

Two continents under one quality system mean you can structure your supply chain around your regulatory strategy, not around which site happens to have an open slot.

Tell us your target batch size, modality and timeline, and we will confirm capacity and lay out a technology transfer plan into GMP.

Why Partner with Us



One Accountable Partner

One contract, one project team and one technology transfer path across biologics, payload, linker, and conjugation.



Built for Every Conjugate Modality

Antibody-drug, peptide-drug and antibody-oligonucleotide conjugates, on the same integrated platform.



Deep Chemistry Experience

A track record spanning hundreds of payload-linker analogs and six conjugation chemistries.



Flexible to Your Program

Tailored commercial structures and dedicated project management, built around your program.

Let's Talk About Your Program

Wherever your ADC program stands today, discovery, scale-up, or GMP supply, we would like to hear about it.

About Syngene

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022) is an integrated CRDMO (Contract Research, Development and Manufacturing Organization), serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene's ~6000 scientists bring the skills and capacity to deliver great science, strong data security, and quality manufacturing, at speed, helping improve time-to-market and lower the cost of innovation. This is backed by ring-fenced dedicated centers, as well as ~3 Mn sq. ft. of specialist discovery, development, and manufacturing facilities.

For more details, visit www.syngeneintl.com or write to us at bdc@syngeneintl.com